Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma
- 12 August 2008
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (16), 5124-5130
- https://doi.org/10.1158/1078-0432.ccr-07-4774
Abstract
Purpose: Novel therapeutic strategies are needed to prevent the tumor recurrence or metastasis after liver transplantation for hepatocellular carcinoma (HCC). This study was to investigate the effect of rapamycin, alone and in combination with sorafenib, on HCC in vivo. Experimental Design: Xenograft of a highly metastatic human HCC tumor (LCI-D20) was used to evaluate primary tumor growth and lung metastasis after treatment with rapamycin alone or in combination with sorafenib. Tumor cell proliferation was determined by Ki-67 immunostaining. To detect tumor cell apoptosis, the terminal deoxynucleotidyl-transferase–mediated dUTP nick-end labeling assay was used. Tumor angiogenesis was investigated by using a monoclonal anti-CD31 antibody. A vascular endothelial growth factor ELISA kit was used to measure vascular endothelial growth factor protein levels in the mice serum. Results: Rapamycin, alone and in combination with sorafenib, strongly inhibited primary tumor growth and lung metastases in LCI-D20 model. Furthermore, the combination therapy significantly enhanced the effect of antitumor on primary tumor growth compared with single treatment with either rapamycin (P < 0.001) or sorafenib (P < 0.001). Rapamycin alone inhibited HCC cell proliferation, induced apoptosis, and decreased tumor angiogenesis. Nevertheless, the combination therapy showed a significant inhibition of tumor cell proliferation (P < 0.05). Additionally, the combination therapy also further enhanced suppression of tumor cell angiogenesis compared with rapamycin treatment (P < 0.01). However, the induction of apoptosis in combination therapy group was not significantly higher than in the rapamycin-treated group (P > 0.05). Conclusions: The combination therapy of rapamycin and sorafenib could be a new and promising therapeutic approach to the treatment of HCC and prevention of HCC recurrence after liver transplantation.Keywords
This publication has 18 references indexed in Scilit:
- Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinomaJournal of Hepatology, 2007
- De Novo Sirolimus-Based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side EffectsTransplantation, 2007
- Rapamycin inhibits cell growth by induction of apoptosis on hepatocellular carcinoma cells in vitroTransplant Immunology, 2007
- Opportunities and Obstacles to Combination Targeted Therapy in Renal Cell CancerClinical Cancer Research, 2007
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- New therapies for hepatocellular carcinomaOncogene, 2006
- Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumorsAnnals of Oncology, 2005
- mTOR and P70 S6 Kinase Expression in Primary Liver NeoplasmsClinical Cancer Research, 2004
- The Outcome of Liver Transplantation in Patients With Hepatocellular Carcinoma in the United States Between 1988 and 2001: 5-Year Survival Has Improved Significantly With TimeJournal of Clinical Oncology, 2003
- SUPERIORITY OF SIROLIMUS (RAPAMYCIN) OVER CYCLOSPORINE IN AUGMENTING ALLOGRAFT AND XENOGRAFT SURVIVAL IN MICE TREATED WITH ANTILYMPHOCYTE SERUM AND DONOR-SPECIFIC BONE MARROW1Transplantation, 1997